Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration (AMDMetab)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04241536|
Recruitment Status : Not yet recruiting
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
|Condition or disease||Intervention/treatment||Phase|
|Age-related Macular Degeneration||Procedure: Blood draw and urine collection||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||295 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration|
|Estimated Study Start Date :||February 1, 2020|
|Estimated Primary Completion Date :||February 1, 2021|
|Estimated Study Completion Date :||March 1, 2021|
This is an epidemiologic study. No arms are considered.
Procedure: Blood draw and urine collection
Patients will collect blood and urine for metabolome analysis
- comparison of the metabolomic profile of AMD-progressors and non-progressors [ Time Frame: 1 year ]The hypothesis is that AMD-progressors present a distinct plasma and urine metabolomic profile. For this, metabolites in blood and plasma will be detected in order to determine the metabolome profile.Non-targeted MS analysis will be performed using Ultrahigh Performance Liquid Chromatography-Tandem MS (measurement tool).
- define statistically relevant metabolite changes with potential value as biomarkers of AMD progression [ Time Frame: 1 year ]Our hypothesis is that the statistical comparison of the metabolic profiles of AMD-progressors with those of the corresponding final disease stage will allow the identification of potential biomarkers of progression. These may either comprise features (sets of metabolites) common to both groups or distinct features which will form a particular progressors signature.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04241536
|Contact: Patrícia Barreto, MSc||00351239480148 ext email@example.com|
|Contact: Inês Laíns, PhDfirstname.lastname@example.org|